Skip to main content

Table 2 General characteristics of subjects with the number of EF ≥ 50%

From: Association between total ischemic time and in-hospital mortality after emergency PCI in patients with acute ST-segment elevation myocardial infarction: a retrospective study

Characteristic

SBT (minutes)

P

 ≤ 120

121–240

241–360

 ≥ 361

(n = 90)

(n = 310)

(n = 272)

(n = 118)

Male, n (%)

67 (74.4)

228 (73.5)

209 (76.8)

78 (66.1)

0.18

Smoking history, n (%)

50 (55.6)

147 (47.4)

132 (48.5)

46 (39.0)

0.12

Drinking history, n (%)

27 (30.0)

79 (25.5)

76 (27.9)

31 (26.3)

0.82

DM history, n (%)

16 (17.8)

68 (21.9)

45 (16.5)

30 (25.4)

0.16

Hypertension history, n (%)

44 (48.9)

165 (53.2)

127 (46.7)

63 (53.3)

0.39

Myocardial infarction history, n (%)

6 (6.7)

15 (4.8)

16 (5.9)

6 (5.1)

0.89

Atrial fibrillation history, n (%)

0 (0)

2 (0.6)

8 (2.9)

3 (2.5)

0.08

Killip classification, n (%)

     

I

80 (88.9)

267 (86.1)

254 (93.4)

89 (75.4)

 < 0.001

II

7 (7.8)

36 (11.6)

13 (4.8)

12 (10.2)

0.03

III

3 (3.3)

2 (0.6)

4 (1.5)

3 (2.5)

0.22

IV

0 (0)

5 (1.7)

1 (0.3)

14 (11.9)

 < 0.001

LM, n (%)

0 (0)

2 (0.6)

1 (0.4)

1 (0.8)

0.81

LAD, n (%)

42 (46.7)

123 (39.7)

114 (41.9)

60 (50.8)

0.17

LCX, n (%)

10 (11.1)

51 (16.5)

29 (10.7)

11 (9.3)

0.09

RCA, n (%)

38 (42.2)

135 (43.5)

128 (47.1)

46 (39.0)

0.5

Grading of thrombus, n (%)

     

0

2 (2.2)

2 (0.6)

1 (0.4)

0 (0)

0.2

1

1 (1.1)

7 (2.3)

3 (1.1)

2 (1.7)

0.71

2

5 (5.6)

22 (7.1)

36 (13.2)

7 (5.9)

0.02

3

31 (34.4)

119 (38.4)

119 (43.8)

51 (43.2)

0.32

4

47 (52.2)

121 (39.0)

66 (24.3)

35 (29.7)

 < 0.001

5

4 (4.5)

39 (12.6)

47 (17.2)

23 (19.5)

0.006

TIMI classification, n (%)

     

0

0 (0)

4 (1.3)

1 (0.4)

6 (5.1)

0.002

1

0 (0)

3 (1.0)

1 (0.4)

5 (4.2)

0.006

2

2 (2.2)

16 (5.2)

8 (2.9)

8 (6.8)

0.21

3

88 (97.8)

287 (92.5)

262 (96.3)

99 (83.9)

0.01

Slow flow, n (%)

3 (3.3)

30 (9.7)

18 (6.6)

22 (18.6)

0.001

VF, n (%)

6 (6.7)

10 (3.2)

10 (3.7)

5 (4.2)

0.52

Application of IABP, n (%)

0 (0)

5 (1.6)

2 (0.7)

6 (5.1)

0.009

Administration of β-blocker, n (%)

77 (85.6)

240 (77.4)

201 (73.9)

72 (61.0)

0.001

ACEI/ARB, n (%)

68 (75.6)

205 (66.1)

146 (53.7)

58 (49.2)

0.001

Administration of diuretic, n (%)

15 (16.7)

64 (20.6)

58 (21.3)

24 (20.3)

0.82

Administration of nicorandil, n (%)

24 (26.7)

52 (16.8)

19 (7.0)

6 (5.1)

0.001

AKI, n(%)

2 (2.2)

5 (1.6)

10 (3.7)

8 (6.7)

0.062

Age, years, mean ± SD

59.44 ± 11.13

59.77 ± 11.22

59.16 ± 12.03

61.37 ± 12.08

0.38

BMI, kg/m2, mean ± SD

25.09 ± 2.77

25.66 ± 3.22

25.44 ± 3.36

25.53 ± 2.77

0.5

Symptom-to-door time, minutes, mean ± SD

39.63 ± 23.39

82.12 ± 38.93

134.06 ± 69.88

181.08 ± 138.33

0.001

P, bpm, mean ± SD

75.98 ± 14.76

75.67 ± 14.18

74.87 ± 17.13

76.20 ± 16.65

0.85

SBP, mmHg, mean ± SD

131.54 ± 22.67

128.03 ± 22.95

129.65 ± 21.90

126.66 ± 24.55

0.38

DBP, mmHg, mean ± SD

81.53 ± 15.17

78.85 ± 14.53

81.03 ± 14.59

77.96 ± 14.72

0.09

Length of lesion, mm, mean ± SD

27.49 ± 11.41

28.70 ± 10.95

28.72 ± 10.36

29.09 ± 9.81

0.73

Syntax score, mean ± SD

20.15 ± 7.89

20.66 ± 7.83

20.24 ± 7.99

22.83 ± 9.09

0.03

WBC, 109/L, mean ± SD

9.77 ± 2.76

10.77 ± 3.33

10.74 ± 3.60

11.37 ± 4.38

0.02

RBC, 1012/L, mean ± SD

4.50 ± 0.53

4.54 ± 0.61

4.49 ± 0.49

4.46 ± 0.56

0.64

HGB, g/L, mean ± SD

138.93 ± 17.51

138.48 ± 18.01

139.05 ± 15.69

138.97 ± 17.26

0.98

PLT, 109/L, mean ± SD

229.69 ± 55.36

225.93 ± 58.73

229.64 ± 63.82

233.48 ± 82.61

0.73

K, mmol/L, mean ± SD

3.96 ± 0.40

3.94 ± 0.45

4.00 ± 0.55

4.06 ± 0.46

0.11

Na, mmol/L, mean ± SD

138.43 ± 3.85

138.87 ± 3.23

139.08 ± 2.96

138.86 ± 3.22

0.43

Cl, mmol/L, mean ± SD

104.14 ± 3.77

102.92 ± 3.61

102.55 ± 5.49

102.63 ± 3.31

0.02

Cr, µmol/L, mean ± SD

76.96 ± 20.62

72.82 ± 17.51

72.53 ± 22.30

72.85 ± 28.57

0.37

UA, µmol/L, mean ± SD

329.09 ± 89.98

313.02 ± 96.22

311.27 ± 84.37

308.79 ± 94.02

0.38

CHOL, mmol/L, mean ± SD

4.59 ± 0.97

4.59 ± 1.01

4.55 ± 0.98

4.50 ± 1.07

0.83

TG, mmol/L, mean ± SD

1.82 ± 1.11

1.66 ± 1.12

1.59 ± 0.91

1.78 ± 1.07

0.19

HDL, mmol/L, mean ± SD

1.02 ± 0.25

1.04 ± 0.25

1.03 ± 0.23

0.97 ± 0.20

0.06

LDL, mmol/L, mean ± SD

3.05 ± 0.81

2.98 ± 0.92

3.01 ± 0.88

2.87 ± 0.94

0.43

CK-MB, ng/mL, mean ± SD

163.33 ± 63.29

164.41 ± 74.37

166.03 ± 47.63

177.44 ± 89.39

0.31

GLU, mmol/L, mean ± SD

7.30 ± 3.09

8.28 ± 3.43

8.12 ± 3.14

8.75 ± 3.77

0.02

  1. Continuous variables are presented as mean ± standard deviation and categorical variables as %. ANOVA test (comparison of > 2 groups) for continuous and ordinal variables and the chi-squared test for categorical variables
  2. SBT: symptom to balloon time; BMI: body mass index; DM: diabetes mellitus; LM: left main coronary artery; LAD: left anterior descending coronary artery; LCX: left circumflex branch coronary artery; RCA: right coronary artery; TIMI: thrombolysis in myocardial infarction; IABP: intra-aortic balloon pump, VF: ventricular fibrillation; ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, EF: ejection fraction, CK-MB: creatinine kinase MB; P: pulse; SBP: systolic blood pressure; DBP: diastolic blood pressure; WBC: white blood cell; RBC: red blood cell; HGB: hemoglobin; PLT: blood platelet; K: potassium; Na: sodium; Cl: chlorine; Cr: creatinine; UA: uric acid; CHOL: cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; TG: triglycerides; GLU: glucose. P-value < 0.05 was considered statistically significant
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us